C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• SARS-CoV-2 infection can lead to severe pneumonia, requiring intensive care unit (ICU) admission and mechanical ventilation.
• Complement activation is implicated in the pathogenesis of COVID-19, suggesting its potential role in disease progression.
• Identifying reliable biomarkers is crucial for predicting COVID-19 outcomes and guiding clinical management.

Purpose of the Study:

• To assess the predictive potential of complement factors C3a and C5b-9 for COVID-19 progression and patient outcomes.
• To evaluate the diagnostic accuracy of C3a and C5b-9 levels for critical illness, intubation, and mortality in COVID-19 patients.

Main Methods:

• A cohort of 80 COVID-19 patients was analyzed, categorized by disease severity (severe vs. critically ill), ventilation status (non-intubated vs. intubated), and survival.
• Serum levels of complement factors C3a and C5b-9 were measured.
• Receiver Operating Characteristic (ROC) curve analysis was employed to determine the predictive accuracy of these markers for clinical outcomes.

Main Results:

• Significantly elevated levels of C3a and C5b-9 were observed in critically ill patients compared to severely ill patients.
• Higher C3a and C5b-9 levels correlated with the need for intubation and increased mortality.
• Both C3a and C5b-9 demonstrated predictive value for ICU admission, intubation, and mortality, with combined use showing enhanced predictive power.

Conclusions:

• Complement factors C3a and C5b-9 are significantly elevated in severe and critical COVID-19 cases.
• These biomarkers serve as valuable prognostic tools for predicting COVID-19 progression, including ICU admission, need for intubation, and mortality.
• The combined assessment of C3a and C5b-9 offers a robust strategy for risk stratification in COVID-19 patients.